The Effect of Arsenic Trioxide on Eliminating HIV-1 Reservoir Combined With cART
Who is this study for? Adults with HIV infection
What treatments are being studied? Arsenic Trioxide
Status: Recruiting
Location: See location...
Intervention Type: Drug
Study Type: Interventional
Study Phase: Phase 1
SUMMARY
To evaluate the safety and efficacy of arsenic trioxide combined with cART in eliminating latent HIV-1 reservoir, providing potential strategies for AIDS functional cure.
Eligibility
Participation Requirements
Sex: All
Minimum Age: 18
Maximum Age: 60
Healthy Volunteers: f
View:
• HIV infection confirmed
• Receiving HAART more than 12 months.
• HIV viral-load \< 50 copies/ml and CD4+ cell count more than 350 cells/ul.
• Without serious heart, lung, liver or kidney disease.
• Participants know about the study and sign informed consent.
Locations
Other Locations
China
Guangzhou 8th People's Hospital
RECRUITING
Guangzhou
Contact Information
Primary
Linghua Li, Doctor
llheliza@126.com
020-83710825
Backup
Weiping Cai, Bachelor
gz8hcwp@126.com
020-83710816
Time Frame
Start Date: 2019-04-01
Estimated Completion Date: 2025-12-31
Participants
Target number of participants: 20
Treatments
Experimental: Arsenic trioxide combined with cART
Receiving intravenous arsenic trioxide, 0.16mg/kg/day, no more than 10 mg per-day , two to four weeks, combined with continuous cART after attaining plasma HIV-1 suppression (plasma HIV RNA \<50 cp/ml) and CD4+ cell count more than 350 cells/ul over 1 year by cART, without active HCV or HBV infection or opportunistic infections.
No_intervention: Without arsenic trioxide therapy
Only receiving cART without arsenic Trioxide after attaining plasma HIV-1 suppression (plasma HIV RNA \<50 cp/ml) and CD4+ cell count more than 350 cells/ul over 1 year by cART, without active HCV or HBV infection or opportunistic infections.
Related Therapeutic Areas
Sponsors
Collaborators: Guangzhou Institutes of Biomedicine and Health Chinese Academy of Sciences
Leads: Guangzhou 8th People's Hospital